Literature DB >> 16940437

Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology.

Charbel E-H Moussa1, Qinghao Fu, Pravir Kumar, Alexander Shtifman, Jose R Lopez, Paul D Allen, Frank LaFerla, David Weinberg, Jordi Magrane, Tamar Aprahamian, Kenneth Walsh, Kenneth M Rosen, Henry W Querfurth.   

Abstract

Intracellular deposition of the beta-amyloid (Abeta) peptide is an increasingly recognized pathological hallmark associated with neurodegeneration and muscle wasting in Alzheimer's disease (AD) and inclusion body myositis (IBM), respectively. Previous reports have implicated dysregulation of beta-amyloid precursor protein (betaAPP) expression in IBM. Accumulation of full-length betaAPP, its various proteolytic derivatives including Abeta, and phospho-tau into vacuolated inclusions is an early pathogenic event. We previously reported on a statistical tendency favoring fast twitch fiber involvement in IBM, reminiscent of the tissue specific patterns of misfolded protein deposition seen in neurodegenerative diseases. To test this principle, we generated an animal model in which human wild-type (WT) betaAPP expression was limited to postnatal type II skeletal muscle. Hemizygous transgenic mice harboring increased levels of holo betaAPP751 and Abeta in skeletal muscle fibers became significantly weaker with age compared with nontransgenic littermates and exhibited typical myopathic features. A subpopulation of dissociated muscle fibers from transgenic mice exhibited a 2-fold increase in resting calcium and membrane depolarization compared with nontransgenic littermates. Taken together, these data indicate that overexpression of human betaAPP in fast twitch skeletal muscle of transgenic mice is sufficient for the development of some features characteristic of IBM, including abnormal tau histochemistry. The increase in resting calcium and depolarization are novel findings, suggesting both a mechanism for the weakness and an avenue for therapeutic intervention in IBM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940437     DOI: 10.1096/fj.06-5763fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  20 in total

1.  Foxo/atrogin induction in human and experimental myositis.

Authors:  Han-Kyu Lee; Edward Rocnik; Qinghao Fu; Bumsup Kwon; Ling Zeng; Kenneth Walsh; Henry Querfurth
Journal:  Neurobiol Dis       Date:  2012-05       Impact factor: 5.996

2.  Primary over-expression of AβPP in muscle does not lead to the development of inclusion body myositis in a new lineage of the MCK-AβPP transgenic mouse.

Authors:  Yue-Bei Luo; Russell D Johnsen; Lisa Griffiths; Merrilee Needham; Victoria A Fabian; Sue Fletcher; Steve D Wilton; Frank L Mastaglia
Journal:  Int J Exp Pathol       Date:  2013-10-31       Impact factor: 1.925

3.  APP(DeltaNL695) expression in murine tissue downregulates CNBP expression.

Authors:  Dana M Niedowicz; Tina L Beckett; Chris J Holler; Adam M Weidner; M Paul Murphy
Journal:  Neurosci Lett       Date:  2010-07-16       Impact factor: 3.046

4.  Orthograde dihydropyridine receptor signal regulates ryanodine receptor passive leak.

Authors:  José Miguel Eltit; Hongli Li; Christopher W Ward; Tadeusz Molinski; Isaac N Pessah; Paul D Allen; José R Lopez
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

5.  Increased expression and local accumulation of the prion protein, Alzheimer Aβ peptides, superoxide dismutase 1, and nitric oxide synthases 1 & 2 in muscle in a rabbit model of diabetes.

Authors:  Claudine L Bitel; Yicheng Feng; Nizar Souayah; Peter H Frederikse
Journal:  BMC Physiol       Date:  2010-09-06

Review 6.  Inclusion body myositis: review of recent literature.

Authors:  Steven A Greenberg
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

7.  Amyloid-β protein impairs Ca2+ release and contractility in skeletal muscle.

Authors:  Alexander Shtifman; Christopher W Ward; Derek R Laver; Mark L Bannister; Jose R Lopez; Masashi Kitazawa; Frank M LaFerla; Noriaki Ikemoto; Henry W Querfurth
Journal:  Neurobiol Aging       Date:  2008-12-23       Impact factor: 4.673

8.  Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model.

Authors:  Masashi Kitazawa; Vitaly Vasilevko; David H Cribbs; Frank M LaFerla
Journal:  J Neurosci       Date:  2009-05-13       Impact factor: 6.167

9.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20

10.  Increased plasma amyloid-beta42 protein in sporadic inclusion body myositis.

Authors:  Wilson F Abdo; Tom van Mierlo; Gerald J Hengstman; H Jurgen Schelhaas; Baziel G van Engelen; Marcel M Verbeek
Journal:  Acta Neuropathol       Date:  2009-06-06       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.